Lucitanib
- Generic Name
- Lucitanib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H25N3O4
- CAS Number
- 1058137-23-7
- Unique Ingredient Identifier
- PP449XA4BH
- Background
Lucitanib has been used in trials studying the treatment of ER+, MBC, SCLC, HER2+, and NSCLC, among others.
- Associated Conditions
- -
- Associated Therapies
- -
A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT04151563
- Locations
- 🇷🇴
Local Institution, Timisoara, Romania
A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor
- Conditions
- Interventions
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Clovis Oncology, Inc.
- Target Recruit Count
- 227
- Registration Number
- NCT04042116
- Locations
- 🇺🇸
Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
- Conditions
- Interventions
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 25
- Registration Number
- NCT03992131
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Study of the AL3810 in the Treatment of Advanced Solid Tumor
- First Posted Date
- 2017-04-17
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Haihe Biopharma Co., Ltd.
- Target Recruit Count
- 17
- Registration Number
- NCT03117101
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations
- First Posted Date
- 2016-04-22
- Last Posted Date
- 2018-08-02
- Lead Sponsor
- Teresa Helsten, MD
- Registration Number
- NCT02747797
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2020-06-23
- Lead Sponsor
- Clovis Oncology, Inc.
- Target Recruit Count
- 178
- Registration Number
- NCT02202746
- Locations
- 🇺🇸
Arizona Oncology Associates, Sedona, Arizona, United States
🇺🇸Moores UCSD Cancer Center, La Jolla, California, United States
🇺🇸Cancer Care Associates Medical Group, Inc., Redondo Beach, California, United States
A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations
- First Posted Date
- 2014-04-09
- Last Posted Date
- 2019-07-29
- Lead Sponsor
- Clovis Oncology, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT02109016
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Associates in Oncology and Hematology, Rockville, Maryland, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer
- First Posted Date
- 2014-02-04
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 76
- Registration Number
- NCT02053636
- Locations
- 🇫🇷
Institut Claudius Regaud Dpt d'Oncologie Médicale, Toulouse, France
🇫🇷Institut Gustave Roussy Dépt d'oncologie - Cancer du sein, Villejuif, France
🇧🇪Institut Jules Bordet, Brussels, Belgium
Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors
- First Posted Date
- 2011-01-26
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 134
- Registration Number
- NCT01283945
- Locations
- 🇫🇷
Hopital Louis Pradel, Lyon, France
🇫🇷Institute Gustave Roussy, Villejuif, Paris, France
🇮🇹European Institute of Oncology, Milano, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.